SPDR S&P Biotech ETF (XBI)

by | Aug 9, 2022 | Daily Trade Alerts

Investors may want to pay close attention to biotech.

Especially with the latest biotech M&A boom.

“Asset sales, cash distributions, reverse mergers, M&A and several positive datasets have helped lift Biotech off of once unfathomably low levels and back towards respectability despite still being off close to 30% YTD,” Oppenheimer says, as quoted by Barron’s.

Amgen, for example, just bought ChemoCentryx (CCXI) for $4 billion. Vertex is buying ViaCyte for $320 million. Pfizer is acquiring Global Blood Therapeutics in a deal valued at $5.4 billion.

The list goes on…

While investors can always hunt for the next potential M&A takeover, another way to potentially profit from the story is with an ETF, such as the SPDR S&P Biotech ETF (XBI). With an expense ratio of 0.35%, some of the ETFs top holdings include Global Blood Therapeutics, Twist Bioscience, Chemocentryx, Beam Therapeutics, Fate Therapeutics, and Editas Medicine to name a few.

[sponsor]

The Forever Battery: Making Gas Guzzlers Obsolete

Only 2% of cars sold in the U.S. today are electric vehicles… but that’s about to change — FAST.

A new battery breakthrough is ready to hit the market. It could revolutionize the $2 trillion automotive industry … and could soon make gas guzzlers obsolete.

This technology is predicted to cause a 1,500% surge in electric vehicle sales over the next four years. The company pioneering this new battery could be the investment of a lifetime.

Click here for details.

Sponsored Content